Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Novo Nordisk ( (NVO) ).
On May 22, 2026, Novo Nordisk announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion recommending EU marketing authorisation for Wegovy 7.2 mg in a once‑weekly single‑dose pen for people living with obesity. The higher‑dose formulation, already marketed in the U.S. as Wegovy HD and approved in the U.K., is expected to launch in the EU in the third quarter of 2026, simplifying dosing from three 2.4 mg injections to a single injection and potentially strengthening Novo Nordisk’s leadership in the fast‑growing obesity treatment market.
The recommendation is supported by the STEP UP phase 3 programme, in which once‑weekly semaglutide 7.2 mg produced a 20.7% mean weight loss in adults with obesity and a 14.1% mean weight loss in participants with both obesity and type 2 diabetes, with about one‑third of trial subjects achieving at least 25% weight reduction. By extending its Wegovy franchise with a more convenient high‑dose pen that maintains a well‑established safety and tolerability profile, Novo Nordisk is positioned to deepen penetration in obesity care, attract additional patients seeking substantial weight loss, and reinforce its competitive edge as rival obesity and metabolic therapies advance toward the European market.
The most recent analyst rating on (NVO) stock is a Hold with a $45.00 price target. To see the full list of analyst forecasts on Novo Nordisk stock, see the NVO Stock Forecast page.
Spark’s Take on NVO Stock
According to Spark, TipRanks’ AI Analyst, NVO is a Outperform.
The score is driven primarily by strong underlying profitability and multi-year growth (financial performance), supported by very attractive valuation (low P/E and high dividend). Offsetting these positives are weaker recent free-cash-flow conversion and higher leverage, plus a cautious 2026 outlook calling for declining sales and operating profit; technically, momentum is positive but appears overbought and still below the 200-day trend.
To see Spark’s full report on NVO stock, click here.
More about Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark, with a heritage in diabetes care and a focus on serious chronic diseases such as obesity and metabolic disorders. The company employs about 67,900 people across 80 countries, markets its therapies in roughly 170 countries, and is listed on Nasdaq Copenhagen and the New York Stock Exchange through its B shares and ADRs.
Average Trading Volume: 20,260,487
Technical Sentiment Signal: Sell
Current Market Cap: $199.1B
Find detailed analytics on NVO stock on TipRanks’ Stock Analysis page.